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A b s t r a c t
Background: Heart failure (HF) is a chronic disease of great clinical and economic significance for both the healthcare system 
and patients themselves. 
Aim: To determine the consumption of medical resources for treatment and care of HF patients and to estimate the related costs. 
Methods: The study involved 400 primary care practices and 396 specialist outpatient clinics, as well as 259 hospitals at all 
reference levels. The sample was representative and supplemented with patient interview data. Based on the consumption 
of particular resources and the unit costs of services in 2011, costs of care for HF patients in Poland were estimated. Separate 
analyses were conducted depending on the stage of the disease (according to NYHA classification I–IV). The public payer’s 
perspective and a one year time horizon were adopted. 
Results: Direct annual costs of an HF patient’s treatment in Poland may range between PLN 3,373.23 and 7,739.49 (2011), 
the main cost item being hospitalisation. The total costs for the healthcare system could be as high as PLN 1,703 million, 
which is 3.16% of the National Health Fund’s budget (Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN). 
Conclusions: The costs of treating heart failure in Poland are high; proper allocation of resources to diagnostic procedures 
and treatment may contribute to rationalisation of the relevant expenditure. 
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INTRODUCTION
Heart failure (HF) is a chronic disease of great clinical signi­
ficance, and poses a major economic problem for both the 
healthcare system and patients themselves. The HF prevalence 
in developed countries is estimated at 1% to 3% and grows 
with age [1, 2]. It has been estimated that 15 million patients 
in Europe and 5.8 million in the United States have heart 
failure [3, 4]. In the UK and Scandinavia, the HF prevalence 
is 0.3–2% in the general population, 2–5% in people aged 
70–79, and 10% in people over 80 years of age [5]. In the US, 
550,000 new cases and more than 950,000 related hospitali­
sations are reported annually [6]. Due to the advanced age of 
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patients, several concomitant diseases, including those leading 
to HF, as well as the chronic nature of this disease combined 
with poor prognosis and frequent hospitalisations, the costs of 
HF diagnostic procedures and treatment are high. Both five 
year survival rate and consumption of healthcare resources 
through hospitalisation are less favourable than in a number 
of common forms of cancer [7]. 
In terms of direct medical costs alone, $20 billion was 
spent on HF treatment in the US in 2000 [8] and $39 billion in 
2010 [4], $2 billion in France in 1990 [5, 9] and $380 million 
in Sweden in 1996 [10]. In Sweden, HF was responsible for 
14% of all hospital days, and hospitalisation accounted for 
over 50% of the direct costs of this disease [10]. Spending on 
care for patients with HF has seen an upward trend, which 
can be attributed mainly to ageing societies in developed 
countries. Heart failure, either acute (37% of admissions) 
or chronic (63% of admissions), is the commonest cause of 
frequently recurring hospitalisation, especially in patients 
over 65 years of age, in a number of European countries. It 
has been estimated that between 1% and 2% of healthcare 
budgets in various countries is spent on HF diagnostic pro­
cedures and treatment [11]. In the UK, it was 1.91% of total 
National Health Service expenditure, while direct medical 
costs borne by the payer (excluding out-of-pocket expenses 
of patients) totalled £905 million, the main item (69%) be­
ing the costs of hospitalisation [12]. According to another set 
of data, a total of 5,336.000 prescriptions associated with 
HF were issued in the UK in 2000, which involved a total 
cost of approximately £54 million. In the same period, 
86,101 hospital admissions, generating costs of £379 million, 
and 7,644.000 consultations, totalling £104 million, were 
reported [13–15]. Numerous other sources confirm these 
figures, which demonstrate the great economic burden of 
medical care for patients with HF. 
This study was aimed at determining the consumption of 
medical resources for the treatment and care of HF patients 
and estimating the related costs. 
METHODS 
The study involved both randomly selected outpatient units 
(400 primary care practices and 396 specialist outpatient cli-
nics), accounting for the annual cost of treatment, and inpa­
tient facilities (259 hospitals at all reference levels), accounting 
for the estimated cost of a single hospitalisation of a patient 
with HF. The sample was representative and supplemented 
with patient interview data. A detailed description of the 
research methods and materials is given elsewhere [16, 17]. 
Based on the consumption of particular resources determined 
in the POLKARD study and the unit costs of services in 2011, 
costs of care for HF patients in Poland were estimated. For 
outpatient care, the costs of diagnostic procedures as well 
as medical appointments and consultations were included. 
Separate analyses were conducted depending on the stage of 
the disease (according to NYHA classes I–IV) and depending 
on the attending physician (general practitioner/specialist). 
The perspective of the public payer, i.e. the National 
Health Fund (NHF), was adopted, and the direct medical 
costs of treatment of patients with HF were considered. 
A time horizon was restricted to one year so no discount­
ing was applied. The unit cost estimates of cost-generating 
diagnostic procedures requested by physicians in outpatient 
settings were derived from the Regulation of the President of 
the NHF (Regulation 62/2009/DSOZ of the President of the 
National Health Fund of 2 November 2009 on the conditions 
of concluding and performing contracts for outpatient specia­
list care. http://www.nfz.gov.pl/new/index.php?katnr=3&dzi
alnr=12&artnr=3901, 15.11.2010). As a per capita scheme 
is used in settlements with general practitioners (primary care 
units), and it is not possible to allocate the per capita fee to 
different diseases in a group of patients attended by the given 
physician, the unit cost of such appointments was assumed to 
correspond to the lowest cardiology consultation fee (assigned 
also to specialist appointments). 
The cost per point for cardiology services (within an 
outpatient specialist setting) was determined as the mean cost 
per point for such services for all centres in Poland (based 
on the National Health Fund — Public Information Bulletin 
— 2010 Contract Guide. http://www.nfz.gov.pl/new/index.ph
p?katnr=3&dzialnr=19&artnr=1483, 5.11.2010), weighted 
by the number of contracts with the centre. Calculations for 
all cost groups were based on the aforementioned unit costs 
as well as data on resource consumption within outpatient 
care collected through physician and patient questionnaires. 
For inpatient care, the division into reference levels was 
accounted for, in that all facilities were divided into academic 
centres as well as regional, district and city hospitals. The 
calculations were based on the service score in points (ac­
cording to the Regulation 51/2010/DSOZ of the President of 
the National Health Fund of 1 September 2010 on amend­
ing the regulation on the conditions of concluding and 
performing contracts for hospital treatment; http://www.nfz.
gov.pl/new/index.php?katnr=3&dzialnr=12&artnr=4200, 
15.11.2010), the value of the NHF’s contracts with healthcare 
centres in Poland in 2010 (the 2010 Contract Guide), and the 
number of particular medical procedures established in the 
POLKARD study. If a particular procedure could be assigned 
to scheduled hospitalisation, the relevant score in points was 
preferred over service score within emergency hospitalisation 
or ‘one-day treatment’ setting. For hospitalisations other than 
for HF [for which no data on administered procedures had 
been collected, so it was not possible to determine diagnosis 
related groups (DRG) for such hospitalisations], the cost cor­
responding to the mean cost of hospitalisation according to 
the 2009 Annual Report of the National Health Fund was 
assigned (http://www.nfz.gov.pl/new/index.php?katnr=3&dzi
alnr=11&artnr=4137, 10.01.2011). In a similar way, the cost 
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of hospitalisation of patients in anaesthesiology and intensive 
care units (AICU) was assessed. The cost of one point (from 
the 2010 Contract Guide) was multiplied by the mean score 
of one man-day of hospitalisation in AICU (the mean score 
across all TISS groups according to the catalogue of services 
to be summed up in line with the Regulation 51/2010/DSOZ 
of the President of the National Health Fund of 1 Septem­
ber 2010 on amending the regulation on the conditions of 
concluding and performing contracts for hospital treatment; 
http://www.nfz.gov.pl/new/index.php?katnr=3&dzialnr=12&
artnr=4200, 15.11.2010), and the total number of hospital 
days for the relevant populations. 
The cost of a single hospitalisation would cover the cost 
of treatment in AICU and/or the cost of treatment in other 
wards (outside AICU). The cost of treatment in non-AICU 
wards depended on medical procedures conducted during 
hospitalisation, which determined the DRG for settlements for 
the given patient. The costs of hospitalisation were determined 
by taking a maximalist approach, i.e. assuming that each of 
the procedures listed below required a separate hospitalisa­
tion; if the mean number of hospitalisations exceeded the 
mean aggregate number of procedures, non-treatment hos­
pitalisation was assigned the mean cost for HF groups (there 
are two DRGs for HF, namely ‘Heart failure > 69 years or 
complicated’ and ‘Heart failure < 70 years, uncomplicated’). 
Additionally, a minimalist approach was tested (sensitivity 
analysis) by assuming that coronarography and angioplasty 
were performed as a part of hospitalisation for other reasons 
(and thus generated no additional costs). 
The costs of medicines, diagnostic procedures and treat­
ments received by patients in inpatient facilities are included 
in hospitalisation costs, which are reflected in scores of par­
ticular DRGs (the relevant database also includes information 
about particular medicines and diagnostic procedures used 
in hospitals). 
Owing to differences related to the choice of a sample 
and, consequently, the characteristics of groups of respon-
dents, the data concerning patients included in the outpa­
tient arm and the inpatient arm of the study were processed 
separately, provided that the analysis of the annual costs of 
treatment of HF, which was based on the outpatient data, 
used the AICU treatment data collected for patients included 
in the inpatient arm of the study. The costs of drug treatment 
were considered as a whole, assuming that the structure of 
usage and reimbursement expenditure at the moment of 
collecting data on resources was similar to that at the mo­
ment of calculations. The analysis did not account for the 
costs of medical transport, but information on the number 
of emergency ambulance dispatches to patients with HF was 
collected in the study. 
RESULTS
The results related to the enrolment of health care centres into 
the study and the data collected from them (5,275 question­
naires), the characteristics of an additional group of patients 
(1,024 questionnaires) as well as the description of diagnosing 
and managing patients are given elsewhere [16, 17]. 
The tables below present the annual consumption of 
resources for the treatment of HF patients by NYHA class. The 
mean number of hospitalisations and medical appointments 
depending on the NYHA class is presented in Table 1. Further­
more, the diagnostic procedures requested by specialists and 
general practitioners are presented in Table 2. Although basic 
diagnostic procedures do not affect the costs of treatment, 
as their cost is included in the cost of medical appointments, 
the data on the mean number of such procedures provides 
information about the diagnostic regimens followed by pri­
mary and specialist care physicians, and thus constitute an 
added value of the analysis. 
The mean number of therapeutic procedures in HF 
patients per annum is presented in Table 3. 
The average number of days spent by patients in anaesthe­
siology and intensive care units during a single hospitalisation, 
depending on the patient’s NYHA class, is presented in Table 4. 
Table 1. Annual consumption of resources: hospitalisations and medical appointments 
Item Average number per patient, annually (range) 
NYHA I 
(n = 61)
NYHA II 
(n = 2,004)
NYHA III 
(n = 1,569)
NYHA IV 
(n = 173)
Total 
(n = 3,915)
Hospitalisation for heart failure 0.32 (0–8) 0.45 (0–12) 0.89 (0–10) 1.84 (0–10) 0.68 (0–12)
Hospitalisation for other reasons 0.36 (0–4) 0.3 (0–6) 0.35 (0–18) 0.27 (0–5) 0.33 (0–18)
Outpatient appointments (scheduled) 8.49 (0.5–110) 8.27 (0–110) 9.48 (0–52) 10.951 (0–26) 8.90 (0–110)
Outpatient appointments (emergency) 0.66 (1–8) 0.68 (1–26) 1.55 (1–33) 2.81 (1–30) 1.12 (1–33)
Home visits (scheduled) 0.36 (0–12) 0.31 (0–22) 0.78 (0–48) 1.37 (0–30) 0.55 (0–48)
Home visits (emergency, due to intensification  
of heart failure symptoms) 
0.17 (0–8) 0.16 (0–12) 0.52 (0–12) 1.15 (0–15) 0.35 (0–15)
Home visits (emergency, for other reasons) 0.10 (0–3) 0.14 (0–10) 0.28 (0–15) 0.43 (0–12) 0.21 (0–15)
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The payer’s expenditure on pharmaceutical drugs, by 
ATC group and NYHA class, is presented in Table 5. 
The POLKARD study involved also inpatient facilities, for 
which the cost of an HF patient’s single hospitalisation was 
estimated. The therapeutic procedures conducted during 
such hospitalisations, by NYHA classes of HF patients and 
by the reference levels of hospitals in which patients were 
hospitalised, are presented in the tables below. It is worth 
noting that because the number of NYHA I patients included 
in the analysis is small, the estimates based on this sample 
may differ from the actual consumption of resources for care 
of this class of patients (Tables 6, 7). 
The average annual costs of an HF patient’s treatment 
are presented in Figure 1, while Table 8 presents their break­
down into costs of different services, namely treatment in 
anaesthesiology and intensive care units, hospitalisations for 
HF, hospitalisation for other reasons (this item was accounted 
for, as concomitant diseases often result from a patient’s 
chronic disease, which is often treated during hospitalisation 
for other reasons), outpatient appointments, home visits and 
cost­generating diagnostic procedures.
Treatment of patients in AICUs accounts for the largest share 
of total costs. The higher the NYHA class of patients, the higher 
the share of the cost of AICU treatment; for NYHA IV, it is as 
much as 70% of total costs. Share of the costs of hospitalisation 
in other wards gradually decreases owing to a lower number of 
procedures being administered to patients with severe HF, and 
thus lower costs of non-AICU hospitalisation. 
In the analysis conducted for the inpatient arm of the 
study, the cost of a single hospitalisation of a patient with 
HF was determined. The hospitalisation cost, by NYHA class 
of patients and by the reference level of hospitals in which 
patients were hospitalised, are presented in Table 9 and 
Table 10, respectively. 
Estimating the unit cost of hospitalisation made it pos­
sible to determine the relation between the annual cost of 
hospitalisations and their number, as well as the impact of the 
cost of a single hospitalisation on the annual cost of treatment 
Table 2. Annual consumption of resources: diagnostic procedures requested by general practitioners and specialists 
Type of procedure Average number per patient, annually (range) 
Specialists 
(n = 1,970)
GPs 
(n = 1,993)
Total  
(n = 3,963)
Complete blood count 1.40 (0–20) 1.86 (0–30) 1.63 (0–30)
ASPAT 0.98 (0–10) 1.22 (0–24) 1.1 (0–24)
Serum bilirubin 0.62 (0–11) 0.76 (0–32) 0.69 (0–32)
Serum glucose 4.42 (0–650) 8.29 (0–865) 6.36 (0–865)
Serum sodium 1.74 (0–30) 1.69 (0–18) 1.72 (0–30)
Serum potassium 1.83 (0–30) 1.85 (0–24) 1.84 (0–30)
Serum creatinine 1.52 (0–53) 1.59 (0–24) 1.56 (0–53)
Serum uric acid 0.51 (0–10) 0.65 (0–24) 0.58 (0–24)
Serum urea 0.98 (0–12) 1.18 (0–24) 1.08 (0–24)
Proteinogram or serum albumin level 0.23 (0–5) 0.30 (0–12) 0.27 (0–12)
Lipid profile 1.25 (0–32) 1.62 (0–18) 1.44 (0–32)
TSH and/or fT4 0.45 (0–12) 0.49 (0–10) 0.47 (0–12)
B-type natriuretic peptide 0.11 (0–6) 0.04 (0–6) 0.07 (0–6)
General urine test 1.16 (0–12) 2.18 (0–24) 1.67 (0–24)
Troponin 0.44 (0–20) 0.36 (0–12) 0.4 (0–20)
CPK and/or CPK-MB 0.40 (0–10) 0.41 (0–13) 0.4 (0–13)
International normalised ratio 0.45 (0–24) 0.54 (0–50) 0.49 (0–50)
Electrocardiogram (ECG) 4.29 (0–40) 3.97 (0–60) 4.12 (0–60)
Chest X-ray 0.86 (0–15) 0.91 (0–11) 0.89 (0–15)
Echocardiography 1.11 (0–16) 0.67 (0–12) 0.89 (0–16)
Spirometry 0.11 (0–4) 0.26 (0–9) 0.19 (0–9)
Holter ECG 0.46 (0–5) 0.25 (0–12) 0.36 (0–12)
Exercise test 0.26 (0–4) 0.23 (0–12) 0.24 (0–12)
Abdominal ultrasonography 0.01 (0–3) 0.02 (0–4) 0.02 (0–4)
ASPAT — asparagine-oxo-acid transaminase; CPK — creatine phosphokinase; GP — general practitioner; TSH — thyroid-stimulating hormone, thyrotropin
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Table 3. Annual consumption of resources: therapeutic procedures 
Type of procedure Average number of procedures per patient, annually (range) 
NYHA I 
(n = 163)
NYHA II 
(n = 2,025)
NYHA III 
(n = 1,584)
NYHA IV 
(n = 174)
Total  
(n = 3,971)
Coronarography 0.27 (0–2) 0.17 (0–5) 0.14 (0–3) 0.13 (0–2) 0.16 (0–5)
Balloon angioplasty 0.09 (0–4) 0.07 (0–3) 0.05 (0–3) 0.01(0–1) 0.06 (0–4)
Stent implantation 0.13 (0–3) 0.07 (0–3) 0.04 (0–2) 0.01 (0–1) 0.06 (0–3)
Coronary artery bypass grafting 0.03 (0–1) 0.03 (0–2) 0.02 (0–1) 0.02 (0–2) 0.03 (0–2)
Valve procedure 0.04 (0–2) 0.01 (0–2) 0.01 (0–1) 0.01 (0–1) 0.01 (0–2)
Single/dual chamber pacemaker implantation 0 (0–0) 0.00 (0–2) 0.00 (0–1) 0 (0–0) 0.00 (0–2)
Resynchronisation with biventricular stimulation 0 (0–0) 0.00 (0–1) 0.00 (0–1) 0.01 (0–1) 0.00 (0–1)
Cardioverter/defibrillator implantation 0.01 (0–1) 0.01 (0–2) 0.01 (0–2) 0.01 (0–1) 0.01 (0–2)
Table 4. Consumption of resources: treatment of heart failure patients in anaesthesiology and intensive care units 
Item Average number of days per patient during single hospitalisation (range)
NYHA I 
(n = 9)
NYHA II 
(n = 246)
NYHA III 
(n = 649)
NYHA IV 
(n = 366)
Total  
(n = 1,234)
Treatment in an intensive care unit 2.22 (0–11) 1.09 (0–12) 1.22 (0–29) 2.63 (0–35) 1.61 (0–35)
Treatment in an intensive care unit among 
patients requiring intensive care 
5.00 (1–11) 3.89 (1–12) 4.24 (1–29) 5.37 (1–35) 4.67 (1–35)
Table 5. Pharmaceutical drugs 
Group of drugs (ATC code) Cost of drugs (NHF’s perspective), in PLN 
NYHA I 
(n = 163)
NYHA II 
(n = 2,025)
NYHA III 
(n = 1,585)
NYHA IV 
(n = 175)
Total 
(n = 3,948)
Platelet aggregation inhibitors (B01AC) 16.97 15.29 14.43 15.17 15.01
Digitalis glycosides (C01AA) 2.74 4.83 8.14 10.13 6.31
Diuretics (C03) 28.70 52.55 77.33 109.00 64.01
Beta-blocking agents (C07) 18.21 20.24 16.30 9.87 18.11
Angiotensin converting enzyme  
inhibitors (C09AA) 
82.29 72.58 66.66 64.15 70.23
Total 148.92 165.48 182.86 208.33 173.67
Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN
Table 6. Consumption of resources for heart failure patient hospitalisation: therapeutic procedures by NYHA class
Type of procedure Average number of procedures per patient during single hospitalisation (range)
NYHA I 
(n = 9)
NYHA II 
(n = 246)
NYHA III 
(n = 649)
NYHA IV 
(n = 366)
Total 
(n = 1,283)
Coronarography 0.125 (0–1) 0.0935 (0–2) 0.0647 (0–2) 0.0273 (0–1) 0.0608 (0–2)
Balloon angioplasty 0.2222 (0–1) 0.0254 (0–1) 0.0175 (0–2) 0.0172 (0–2) 0.0211 (0–2)
Stent implantation 0.2222 (0–1) 0.0338 (0–1) 0.0254 (0–2) 0.0115 (0–1) 0.0251 (0–2)
Coronary artery bypass grafting 0 (0–0) 0.0042 (0–1) 0.0016 (0–1) 0.0112 (0–1) 0.0048 (0–1)
Valve procedure 0 (0–0) 0 (0–0) 0.0015 (0–1) 0.0028 (0–1) 0.0016 (0–1)
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Table 7. Consumption of resources for heart failure patient hospitalisation: therapeutic procedures by hospital reference level 
Type of procedure Average number of procedures per patient during single hospitalisation (range)
City  
hospital wards  
(n = 304)
District  
hospital wards  
(n = 556)
Regional  
hospital wards 
(n = 292)
Clinical wards 
of medical  
universities  
(n = 128)
Total 
(n = 1,283)
Coronarography 0.0197 (0–1) 0.0018 (0–1) 0.1483 (0–2) 0.2188 (0–1) 0.0608 (0–2)
Balloon angioplasty 0.0137 (0–2) 0.0037 (0–1) 0.0427 (0–2) 0.0708 (0–1) 0.0211 (0–2)
Stent implantation 0.0205 (0–2) 0.0037 (0–1) 0.0432 (0–2) 0.0973 (0–1) 0.0251 (0–2)
Coronary artery bypass grafting 0.0034 (0–1) 0 (0–0) 0.0141 (0–1) 0.008 (0–1) 0.0048 (0–1)
Valve procedure 0 (0–0) 0 (0–0) 0.0034 (0–1) 0.0081 (0–1) 0.0016 (0–1)
Figure 1. Average annual costs of heart failure patient’s treatment by NYHA class; AICU — anasethesiology and intesive care 
units; Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN
Table 8. Average annual costs of heart failure patient’s treatment: detailed breakdown 
Cost item Average annual costs of treatment per patient, in PLN 
NYHA I NYHA II NYHA III NYHA IV Total
Treatment in AICUs 2,181.83 1,504.87 3,279.82 14,800.86 3,360.34
Hospitalisation for heart failure 2,971.94 2,321.77 3,054.55 4,732.18 2,748.49
Hospitalisation for other reasons 1,117.47 936.97 1,085.28 834.38 1,005.91
Outpatient appointments 331.88 324.43 399.86 498.86 362.88
Home visits 40.22 39.26 100.56 187.01 70.17
Outpatient diagnostic procedures 32.00 21.84 12.68 11.55 18.02
Drugs 148.92 165.48 182.86 208.33 173.67
Total cost 6,824.92 5,314.62 8,115.61 21,273.33 7,739.49
AICU — anaesthesiology and intensive care units; Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN
of NYHA I patients (in fact, high annual cost of treatment of 
such patients results from costly interventions in them, which 
add to the cost of hospitalisation itself). 
The average costs of hospitalisation grew with the hospital 
reference level. 
DISCUSSION
The costs of diagnostic and therapeutic procedures used in 
the treatment of HF, from the public payer’s perspective, were 
estimated in this study. Owing to the random selection of both 
inpatient and outpatient facilities, the sample was representa­
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tive at this level and typical of care for HF patients in Poland. 
The analysis of individual cost items matches the data for 
other countries and indicates that the main cost component is 
hospitalisation, followed by medical appointments, laboratory 
tests and others [18, 19]. This data is an indirect confirmation 
of the NHF’s reports, in which the two diagnoses (ICD-10) asso-
ciated with the highest costs, in populations of men and women 
aged over 65, are related to HF [20]. The elderly population 
consumes approximately three quarters of the overall resources 
used for the treatment of this disease [21]. The total medical 
costs of treatment increase with NYHA class, if NYHA I and 
II patients are considered jointly. With this assumption, the 
results match the data for France, Germany, Belgium and the 
Netherlands [19]. This study demonstrated that treatment of 
NYHA  I patients involved higher expenditure compared to 
NYHA II and III patients. This may be attributable to the high­
est number of specialist procedures (cardiology interventions) 
in this group, and thus the highest costs. In medical terms, 
such interventions may inhibit the progress of the disease in 
its early stages, as it is often stimulated by other heart diseases 
which ultimately lead to HF. A maximalist approach applied 
in the cost analysis (i.e. associating each procedure with 
a separate hospitalisation) did not significantly affect the final 
results thereof. A minimalist approach (i.e. assuming zero costs 
of coronarography and angioplasty by including them in the 
costs of hospitalisation for other reasons) led to a difference of 
less than PLN 100 in the estimate of the total annual costs of 
treatment (compared to a maximalist approach). 
In the inpatient population, direct medical costs of an 
HF patient’s single hospitalisation grow with the hospital 
reference level, from the lowest in city hospitals to the high­
est in university hospitals. This trend would have been even 
stronger, if reference level-dependent unit costs, rather than 
average costs of hospitalisation, had been used in calcula­
tions. Such results are consistent with the general assumption 
that expenditure on treatment in more specialised facilities 
is higher. The time of hospitalisation of patients included in 
the POLKARD study was slightly longer than indicated by the 
US data [22] and slightly shorter than in the UK [19], while 
the time of treatment in AICUs was almost the same [22]. 
This is an indirect indication that global standards of duration 
of hospital treatment of HF patients have been achieved in 
Poland. Data concerning unit costs of drugs was not updated 
due to constant changes in the reimbursement scheme of 
particular medicines (leading to changes in the consumption 
pattern) and due to the fact that this was not a major cost 
component from the payer’s perspective (unlike the patient’s 
perspective, as the percentage of out-of-pocket spending for 
these drugs was even higher than the average co-payment rate 
for all drugs in Poland, which is the highest in the European 
Union in itself). 
Limitations of the study
As for the limitations of the study, no indirect costs were ac­
counted for (these will be subject to separate analysis). These 
costs are potentially of great importance in Poland, as only 
23% of Polish HF patients of working  age remain profession­
ally active [23]. Sampling of hospitals, outpatient clinics and 
doctors (not patients) most probably led to epidemiological 
underestimation of NYHA I patients — the results for this 
group of patients should be treated with caution. Moreover, 
it would be useful to conduct an analysis of subpopulations, 
e.g. patients with co-morbidities like diabetes or with systolic 
dysfunction (the majority), excluding the least advanced stage 
Table 9. Average costs of heart failure patient’s hospitalisation, by NYHA class: detailed breakdown 
Cost item Average costs of heart failure patient’s hospitalisation 
NYHA I NYHA II NYHA III NYHA IV Total
Treatment in AICU 6,777.60 3,321.31 3,705.56 8,026.80 4,907.31
Hospitalisation 3,706.87 2,575.65 2,457.96 2,615.01 2,538.86
Total cost 10,484.48 5,896.96 6,163.52 10,641.81 7,446.17
AICU — anaesthesiology and intensive care units; Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN
Table 10. Average costs of heart failure patient’s hospitalisation, by hospital reference level: detailed breakdown
Cost item Average costs of heart failure patient’s hospitalisation 
City hospital 
wards 
District hospital 
wards 
Regional hospi-
tal wards 
Clinical wards of 
medical universities 
Total 
Treatment in AICU 4,590.50 4,273.83 5,350.93 7,881.21 4,907.31
Hospitalisation 2,451.78 2,339.73 2,797.51 3,045.89 2,538.86
Total cost 7,042.28 6,613.56 8,148.44 10,927.11 7,446.17
AICU — anaesthesiology and intensive care units; Ex. rate from 05.03.2012: 1 EUR = 4.14 PLN
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of the disease (NYHA I), without arrhythmia (40.4% meeting 
all these criteria), or including them (49.7%, as a separate 
criterion), as well as costs associated with such subpopula­
tions. Such an approach would facilitate the selection of 
subpopulations posing the heaviest financial burden and, 
consequently, offering the greatest room for rationalisation of 
expenses. Finally, extrapolation of resource consumption from 
a different point in time to combine this data with the current 
unit costs may pose a risk of not accounting for changes in the 
management of HF patients and the financing scheme made 
during this period (more intensive resource use leading to 
underestimation of the results). On the other hand however, 
using the lowest cardiologist’s consultation fee may lead to 
overestimation of this cost group. Due to the limited scope of 
this study, other perspectives were not analysed. Acknowledg­
ing the aforementioned limitations, it should be emphasised 
that this is the most comprehensive and largest sample study 
of the costs of this disease in Poland. 
CONCLUSIONS
To sum up, the direct costs of an HF patient’s treatment in 
Poland ranged from PLN 3,373.23 to 7,739.49 in 2011, 
depending on the assumptions made (inclusion/exclusion of 
additional hospitalisations; avoidance of double payment for 
treatment in AICU and hospital). Assuming a conservative 
estimation of the Polish treated population of HF patients at 
220,000 [24], real unit cost from POLKARD and data reported 
by NHF, the costs for the healthcare system could reach PLN 
1,703 million, which is 3.16% of the NHF’s budget. Owing to 
the fact that HF constitutes such a significant economic bur­
den on both the healthcare system and patients themselves, 
monitoring of trends in this area seems crucial. Due to ageing 
of the Polish population, one can expect higher morbidity of 
HF. More research in this area is needed aimed at the proper 
allocation of limited resources, which will remain a challenge 
for all parties involved in the treatment of this disease in Poland. 
Conflict of interest: none declared
References
1. Cowle MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. 
Eur Heart J, 1997; 18: 208–25. 
2. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac 
failure. Br Heart J, 1994; 72: 3S–9S. 
3. Dickstein K, Cohen-Solal A, Filippatas G et al. ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure 2008; the Task 
Force for the diagnosis and treatment of acute and chronic heart failure 
2008 of the European Society of Cardiology. Developed in collaboration 
with the Heart Failure Association of the ESC (HFA) and endorsed by 
the European Society of Intensive Care Medicine (ESICM). Eur J Heart 
Fail, 2008; 10: 933–989. 
4. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke 
statistics – 2010 update: a report from the American Heart Association, 
Circulation, 2010; 121: e16–e215. 
5. Davis RC, Hobbs FD, Lip GY. ABC of heart failure: history and epidemio-
logy. BMJ, 2000; 320: 39–42. 
6. Weintraub W, Cole J, Todey JF. Cost and cost-effectiveness studies in heart 
failure research. Am Heart J, 2002; 143: 4. 
7. Stewart S, Ekman I, Ekman T et al.. Population Impact of Heart Failure and 
the Most Common Forms of Cancer. A Study of 1 162 309 Hospital Cases in 
Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes, 2010; 3: 573–580. 
8. American Heart Association. 2000. Heart and stroke statistical update. 
Dallas (TX): American Heart Association, 1999. 
9. McMurray JJ, Stewart S. Epidemiology, aertiology, and prognosis of heart 
failure. Heart, 2000; 83: 596–602. 
10. Rydén-Bergsten T, Andersson F. The health care costs of heart failure in 
Sweden. J Intern Med, 1999; 246: 275–284. 
11. Maggioni AP, Dahlstro U, Filippatos G. EUR Observational Research 
Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart 
Fail, 2010; 12: 1076–1084. 
12. Simon Stewarta S, Jenkins A, Buchan S. The current cost of heart failure to 
the National Health Service in the UK. Eur J Heart Fail, 2002; 4: 361–371. 
13. Gnani S, Ellis C, Majeed A. Co-existing conditions of health services as-
sociated with heart failure: general-practice-based study. Health Statistics 
Quarterly, 2001; 12: 27–33. 
14. Netten A, Dennett J, Knight J. Unit costs of health and social care. PSSRU, 
University of Kent, Canterbury, 1999. 
15. McMurray J, Heart W Rhodes G. An evaluation of the cost of heart failure to 
the National Health Service in the UK. Br J Med Economics, 1993; 6: 99–110. 
16. Wizner B, Dubiel JS, Zdrojewski T et al. Ogólnopolski program oceny dia-
gnostyki, leczenia i kosztów u chorych z niewydolnością serca, w losowo 
wybranych jednostkach lecznictwa otwartego i zamkniętego, na poziomie pod-
stawowym, wojewódzkim i specjalistycznym. Założenia i metodyka projektu, 
realizowanego w ramach Narodowego Programu Profilaktyki i Leczenia Chorób 
Układu Krążenia: POLKARD 2003–2005. Folia Cardiol, 2006; 13: 73–81. 
17. Wizner B, Dubiel JS, Opolski G et al. Access to selected diagnostic proce-
dures in the management of heart failure patients in Poland: POLKARD 
2005. Kardiol Pol, 2010; 68: 265–272. 
18. Bjorck Linne A. Liedholm H, Jendteg S, Israelsson B. Health care costs of 
heart failure: results from a randomised study of patient education. Eur 
J Heart Fail, 2000; 2: 291–297. 
19. Berry C, Murdoch DR, McMurray JJV. Economics of chronic heart failure. 
Eur J Heart Fail, 2001; 3: 283–291. 
20. Analiza wydatków Narodowego Funduszu Zdrowia związanych z finan-
sowaniem hospitalizacji pacjentów od 65 roku życia w 2009 r. National 
Health Fund’s Head Office, Department of Healthcare Services. Warsaw, 
November 2010 (20.04.2012). 
21. Liao L, Larry A, Allen LA, Whellan DJ. Economic Burden of Heart Failure 
in the Elderly. Pharmacoeconomics, 2008; 26: 447–462. 
22. Lissovoy G, Kathy Fraeman K, Teerlink JR. Hospital costs for treatment of 
acute heart failure: economic analysis of the REVIVE II study. Eur J Health 
Econ, 2010; 11: 185–193. 
23. Rywik TM, Kołodziej P, Targoński N et al. Characteristics of the heart 
failure population in Poland: ZOPAN, a multicentre national programme. 
Kardiol Pol, 2011; 69: 24–31. 
24. Stanowisko nr 11/6/22/2009 z dnia 9 listopada 2009 r. w sprawie finansowania 
torasemidu (Diuver®) w leczeniu udokumentowanej niewydolności serca 
w klasach NYHA II–NYHA IV http://aotm.gov.pl/assets/files/rada/stanowisko_ 
RK_AOTM_11_6_22_2009_torasemid_Diuver.pdf (05.07.2012).
www.kardiologiapolska.pl232
Adres do korespondencji: 
dr hab. Marcin Czech, Warszawski Uniwersytet Medyczny, ul. Żwirki i Wigury 81, 02–091 Warszawa, e-mail: marcin.czech@wum.edu.pl 
Praca wpłynęła: 30.05.2012 r. Zaakceptowana do druku: 21.11.2012 r.
Koszty niewydolności serca w Polsce  
z punktu widzenia płatnika. 
Program oceny diagnostyki, leczenia i kosztów u chorych  
z niewydolnością serca w losowo wybranych jednostkach  
lecznictwa otwartego i zamkniętego na poziomie podstawowym, 
wojewódzkim i specjalistycznym: POLKARD
Marcin Czech1, Grzegorz Opolski2, Tomasz Zdrojewski3, Jacek S. Dubiel4, Barbara Wizner5,  
Dorota Bolisęga6, Małgorzata Fedyk-Łukasik5, Tomasz Grodzicki5
1Zakład Farmakoekonomiki, Warszawski Uniwersytet Medyczny, Warszawa
2I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny, Warszawa
3Katedra Nadciśnienia Tętniczego i Diabetologii, Gdański Uniwersytet Medyczny, Gdańsk
4II Klinika Kardiologii, Uniwersytet Jagielloński, Kraków
5Katedra Chorób Wewnętrznych i Gerontologii, Uniwersytet Jagielloński, Kraków
6HTA Consulting, Kraków
S t r e s z c z e n i e
Wstęp: Niewydolność serca (HF) jest przewlekłą chorobą o istotnym znaczeniu klinicznym i ekonomicznym zarówno dla 
systemu ochrony zdrowia, jak i samych pacjentów. 
Cel: Celem badania było określenie zużycia zasobów medycznych na leczenie i opiekę nad pacjentem z HF oraz oszacowanie 
kosztów z tym związanych.
Metody: Badanie swym zasięgiem objęło 400 praktyk lekarzy ogólnych/rodzinnych i 396 przychodni specjalistycznych, 
259 szpitali wszystkich poziomów referencyjnych. Próba była reprezentatywna, uzupełniona danymi z wywiadów z pacjenta­
mi. Na podstawie zużycia poszczególnych zasobów i kosztów jednostkowych świadczeń z 2011 r. oszacowano koszty opieki 
nad pacjentem z HF w Polsce. Wykonano osobne analizy w zależności od stopnia nasilenia choroby (wg klas NYHA I–IV); 
w obliczeniach przyjęto perspektywę płatnika publicznego.
Wyniki: Bezpośrednie koszty leczenia pacjenta z HF w Polsce mogą wynosić średnio od 3373,23 do 7739,49 PLN (2011). 
Główną składową tych kosztów jest hospitalizacja. Całkowity koszt dla systemu ochrony zdrowia może wynieść 1703 mln 
PLN, co stanowi 3,16% budżetu NFZ.
Wnioski: Koszty leczenia HF w Polsce są wysokie, właściwa alokacja zasobów w zakresie diagnostyki i leczenia może się 
przyczynić do racjonalizacji przeznaczanych na ten cel wydatków.
Słowa kluczowe: niewydolność serca, koszty, POLKARD, ekonomika zdrowia
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